Interview: Christian L Macher, General Manager, AstraZeneca Taiwan
You have been in Taiwan now for ten months. What are the most important characteristics of this market from your perspective, and what surprised you most about Taiwan? Taiwan is…
AstraZeneca Taiwan has a forward vision and the latest innovations as benchmarks; led by General Manager Christian Macher, it has developed a most professional and efficient pharmaceutical team. The company features and promotes a strong business culture by devoting itself to its core competences and unique advantage. It regards people as the core value of the organization and works at creating a ‘Happy at Work’ environment. This environment can develop people’s potentials and enable the company to be ‘The Best’ pharmaceutical company in Taiwan.
AstraZeneca is one of the world’s leading pharmaceutical companies. Backed by a strong research base and extensive manufacturing and commercial skills, the company provides a powerful range of products for seven important areas of healthcare – Gastrointestinal, Cardiovascular, Cancer, Respiratory, Central Nervous System, Pain Control and Infection.
21st Fl., 207, Tun Hwa South RD., Sec.2 Taipei Metro Building, Taipei 106, Taiwan
Telephone：(02)2378-3374
Fax：(02)2377-0913
Website：www.astrazeneca.com.tw
You have been in Taiwan now for ten months. What are the most important characteristics of this market from your perspective, and what surprised you most about Taiwan? Taiwan is…
Taiwan, an early international market for Kyowa Kirin, now serves as a strategic hub within a Korea-Taiwan-Australia cluster. With a lean team, close government engagement, and clinical trial initiatives, Taiwan…
Professor Chi-Huey Wong serves as President of the Institute for Biotechnology and Medicine Industry (IBMI) in Taiwan, bringing decades of distinguished experience from top-tier US research institutions including MIT, Scripps…
Built around an engineering mindset and a clear view of where a smaller biotech can compete, Pharmosa is pursuing a differentiated path in pulmonary hypertension and related rare diseases through…
Pei-Jiun Chen, CEO and President of Mycenax, outlines the company’s evolution into a focused, end-to-end biologics CDMO with deep roots in development excellence and GMP manufacturing. She highlights Japan as…
With over two decades of global pharmaceutical experience at Eli Lilly and Allergan, Dr Jimmy Chang returned to Taiwan to lead TaiMed Biologics, Taiwan’s first biotech to successfully commercialise a…
Will Hsu leads Sandoz operations across Taiwan, Hong Kong, and Macao, managing a portfolio spanning both generics and biosimilars in markets characterised by universal healthcare and significant budget constraints. With…
Taiwanese biotech Caliway is trying to redefine fat reduction as measurable medicine. Founded in 2012, Caliway has advanced its first-in-class candidate CBL-514 into pivotal Phase III development in the US,…
Frederic Kuo, founder and CEO of Fethiann, established the company in 2017 within Taiwan’s Hsinchu Science Park. With a PhD background and extensive experience in new drug development, Frederick has…
Sean Chang, CEO of Locus Cell, explains how his clinical CAR-T background led him to build a Taiwan-based CDMO for advanced cell therapies. The company is scaling Southeast Asia’s largest…
In 2024, Taipei Medical University reached a defining milestone. President Mai-Szu Wu oversaw a full digital transformation linking seven affiliated medical institutions and more than 3,000 beds into a unified…
Jayashri Kulkarni Managing Director of Johnson & Johnson Taiwan, brings 27 years of experience across pharmaceuticals and medical technology in Asia Pacific. Since assuming her Taiwan role , she has…
With Takeda preparing for global leadership change and Taiwan rapidly upgrading its innovation and access frameworks, General Manager Alexis Lin is navigating one of the most pivotal periods in the…
See our Cookie Privacy Policy Here
